Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

Abstract

In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents1 that inhibit blood vessel growth. However, the implementation of this strategy has faced two major obstacles. First, the long-term shutdown of tumour blood vessels by the anti-angiogenesis agent can prevent the tumour from receiving a therapeutic concentration of the chemotherapy agent. Second, inhibiting blood supply drives the intra-tumoural accumulation of hypoxia-inducible factor-1α (HIF1-α); overexpression of HIF1-α is correlated with increased tumour invasiveness and resistance to chemotherapy2,3,4,5. Here we report the disease-driven engineering of a drug delivery system, a ‘nanocell’, which overcomes these barriers unique to solid tumours. The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumour. The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumour, then releases a chemotherapy agent. This focal release within a tumour results in improved therapeutic index with reduced toxicity. The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an ‘integrative’ approach in cancer therapy.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Synthesis and characterization of a combretastatin–doxorubicin nanocell.
Figure 2: Bioassay of the nanocell with a GFP-positive melanoma–endothelial cell three-dimensional co-culture system.
Figure 3: Nanocell therapy inhibits B16/F10 melanoma and Lewis lung carcinoma growth.
Figure 4: Effect of nanocell treatment on tumour vasculature and apoptosis.

References

  1. 1

    Kerbel, R. S. & Kamen, B. A. The anti-angiogenic basis of metronomic chemotherapy. Nature Rev. Cancer 4, 423–436 (2004)

    CAS  Article  Google Scholar 

  2. 2

    Semenza, G. L. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J. Clin. Invest. 106, 809–812 (2000)

    CAS  Article  Google Scholar 

  3. 3

    Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349–4354 (2002)

    ADS  CAS  Article  Google Scholar 

  4. 4

    Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumour response to antiangiogenic therapy. Science 295, 1526–1528 (2002)

    ADS  CAS  Article  Google Scholar 

  5. 5

    Blagosklonny, M. V. Antiangiogenic therapy and tumour progression. Cancer Cell 5, 13–17 (2004)

    CAS  Article  Google Scholar 

  6. 6

    Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003)

    Article  Google Scholar 

  7. 7

    Rofstad, E. K. et al. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62, 1847–1853 (2002)

    CAS  PubMed  Google Scholar 

  8. 8

    Kieran, M. W., Folkman, J. & Heymach, J. Angiogenesis inhibitors and hypoxia. Nature Med. 9, 1104 (2003)

    CAS  Article  Google Scholar 

  9. 9

    Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nature Rev. Cancer 2, 727–739 (2002)

    CAS  Article  Google Scholar 

  10. 10

    Chabner, B. A., et al. Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th edn (McGraw-Hill, 1996)

    Google Scholar 

  11. 11

    Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21–38 (2002)

    CAS  Article  Google Scholar 

  12. 12

    Miklos, A. G., Lyman, M. D., Freed, L. E. & Langer, R. Wetting of poly(l-lactic acid) and poly(d-lactic-co-glycolic acid) foams for tissue culture. Biomaterials 15, 55–58 (1994)

    Article  Google Scholar 

  13. 13

    Yoo, H. S., Oh, J. E., Lee, K. H. & Park, T. G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm. Res. 16, 1114–1118 (1999)

    CAS  Article  Google Scholar 

  14. 14

    Sengupta, S., Kiziltepe, T. & Sasisekharan, R. A dual-colour fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules. FASEB J. 18, 1565–1567 (2004)

    CAS  Article  Google Scholar 

  15. 15

    Jain, R. K. Normalizing tumour vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7, 987–989 (2001)

    CAS  Article  Google Scholar 

  16. 16

    Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J. Clin. Invest. 105, 1045–1047 (2000)

    CAS  Article  Google Scholar 

  17. 17

    Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Drug Discov. 2, 750–763 (2002)

    CAS  Article  Google Scholar 

  18. 18

    Yuan, F. et al. Vascular permeability in a human tumour xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995)

    CAS  PubMed  Google Scholar 

  19. 19

    Tong, R. T. et al. Vascular normalization by vascular endothelial growth facor receptor-2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731–3736 (2004)

    CAS  Article  Google Scholar 

  20. 20

    Arap, W. et al. Steps toward mapping the human vasculature by phage display. Nature Med. 8, 121–127 (2002)

    CAS  Article  Google Scholar 

  21. 21

    Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank S. R. Kabir, K. Holley and G. T. Franzesi for assistance.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ram Sasisekharan.

Ethics declarations

Competing interests

Reprints and permissions information is available at npg.nature.com/reprintsandpermissions. The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sengupta, S., Eavarone, D., Capila, I. et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568–572 (2005). https://doi.org/10.1038/nature03794

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing